So, You Want to Be an Adjunct Professor?: The Processes, Perils, and Potential

The American Bar Association’s “50 Simple Ways to Market Your Practice” includes as No. 43 “do adjunct professor work.” In addition, law school economics and restructurings are creating new opportunities for adjunct professor work. If you are intrigued by the possibility of adjunct teaching, now may be just the time to explore such an opportunity with a law school. Law students routinely report high interest and satisfaction with courses taught by practicing attorneys. Yet these successful teaching experiences don’t just happen! There are a number of things to consider before sending your resume to the Dean of your local law school. This article describes best practices to help ensure a successful outcome for an attorney interested in adjunct professor work. Incorporating the best practices in this article into your adjunct teaching will create the learning environment students are seeking, enhance your teaching experience, and leverage this networking and career development opportunity. A decision tree/flow chart is included as an Appendix to the article to assist in determining whether to “do adjunct professor work.

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5-0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1-66), progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS estimates at 5 years: 70% vs 12%; HR [95% CI]: 0.146 [0.098-0.218]; OS estimates at 5 years: 83% vs 68%; HR [95% CI]: 0.450 [0.266-0.761]). Ibrutinib benefit was also consistent in patients with high prognostic risk (TP53 mutation, 11q deletion, and/or unmutated IGHV) (PFS: HR [95% CI]: 0.083 [0.047-0.145]; OS: HR [95% CI]: 0.366 [0.181-0.736]). Investigator-assessed overall response rate was 92% with ibrutinib (complete response, 30%; 11% at primary analysis). Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time. Fifty-eight percent of patients continue to receive ibrutinib. Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus chlorambucil and increased depth of response over time

The Demise Of Silicon Graphics Explicated By A Structural Functionalist

It has been asserted that positivism is the philosophical basis of research in the field of Information Systems by Goles and Hirschheim. This is seen as problematic in an area that undergoes swift and constant change because of its technological nature. The rise and fall of Silicon Graphics Incorporated (SGI) is the focus of this paper. The mechanism for explaining change is the action theory of Talcott Parsons, a structural functionalist, whose theory, in turn, is attacked for the inability to account facilely for change.

Google Glass FOR THE Educator: A Postmortem Separating the Reality From the Hype and Some Thoughts for Google

The article offers information on the wearable technology Google Glass and its potential for the education market. Topics include the history of Project Glass when it was announced in April 2012 to its end in January 2015, the flaws of first Glass version from Wi-Fi access requirements to poor quality video and audio capture, and the use of Glass from video tours to interviews

Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis, emphysema and irreversible airflow limitation. These changes are thought to be due to oxidative stress and an imbalance of proteases and antiproteases. Quercetin, a plant flavonoid, is a potent antioxidant and anti-inflammatory agent. We hypothesized that quercetin reduces lung inflammation and improves lung function in elastase/lipopolysaccharide (LPS)-exposed mice which show typical features of COPD, including airways inflammation, goblet cell metaplasia, and emphysema. Methods Mice treated with elastase and LPS once a week for 4 weeks were subsequently administered 0.5 mg of quercetin dihydrate or 50% propylene glycol (vehicle) by gavage for 10 days. Lungs were examined for elastance, oxidative stress, inflammation, and matrix metalloproteinase (MMP) activity. Effects of quercetin on MMP transcription and activity were examined in LPS-exposed murine macrophages. Results Quercetin-treated, elastase/LPS-exposed mice showed improved elastic recoil and decreased alveolar chord length compared to vehicle-treated controls. Quercetin-treated mice showed decreased levels of thiobarbituric acid reactive substances, a measure of lipid peroxidation caused by oxidative stress. Quercetin also reduced lung inflammation, goblet cell metaplasia, and mRNA expression of pro-inflammatory cytokines and muc5AC. Quercetin treatment decreased the expression and activity of MMP9 and MMP12 in vivo and in vitro, while increasing expression of the histone deacetylase Sirt-1 and suppressing MMP promoter H4 acetylation. Finally, co-treatment with the Sirt-1 inhibitor sirtinol blocked the effects of quercetin on the lung phenotype. Conclusions Quercetin prevents progression of emphysema in elastase/LPS-treated mice by reducing oxidative stress, lung inflammation and expression of MMP9 and MMP12.http://deepblue.lib.umich.edu/bitstream/2027.42/78260/1/1465-9921-11-131.xmlhttp://deepblue.lib.umich.edu/bitstream/2027.42/78260/2/1465-9921-11-131.pdfPeer Reviewe